logo-loader
viewOpen Orphan PLC

Full interview: Open Orphan hails huge new deal leading to stronger revenues

Open Orphan (LON:ORPH) has hailed a new three-year contract with a ‘tier-one’ German pharmaceuticals company. Stepping up to Executive Chairman from CEO, Cathal Friel tells Proactive London his new role will be focussing on investor relations and 'telling the story'. He's excited about the story too, talking enthusiastically about where Open Orphan is heading now and re-capping what's happened over the last few weeks. Friel touches on the new deal saying it guarantees “significant annual revenues” with work expected to get underway this month.
Open Orphan unit Venn Life Sciences will provide the new customer pharmacokinetic services which will allow researchers to decide on dosing and assess drug side-effects.

Quick facts: Open Orphan PLC

Price: 6.45 GBX

AIM:ORPH
Market: AIM
Market Cap: £28.74 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Open Orphan confirms hVIVO deal is done

Cathal Friel, CEO of Open Orphan announces that the hVIVO deal is finally in the bag and tells Proactive London what the timeline for shareholders now looks like. News here on the Genomic Database and how Friel expects hVIVO to make a profit. Confirmation too on the slight musical chairs within...

1 week, 3 days ago

2 min read